China approves norovirus vaccine for clinical trial

CNC
Added On June 6, 2019

Chinese authorities have given the green light to a clinical trial for the world's first tetravalent vaccine against norovirus, the most common cause of viral gastroenteritis.
 
The vaccine received the clinical research permit from the National Medical Products Administration on May 30th.
 
It is jointly developed by the Institut Pasteur of Shanghai (IPS) under the Chinese Academy of Sciences and Anhui Zhifei Longcom Biopharmaceutical Co. Ltd. 
 
As the number one cause of acute viral gastroenteritis, the highly contagious and sometimes deadly norovirus infects about 685 million people worldwide annually and has increasingly emerged as a public health issue in China.
 
The vaccine can theoretically prevent 80 to 90 percent of norovirus infections also known as "stomach flu."
 
The clinical trial is expected to last for five years before the vaccine can apply for new drug registration, which will benefit norovirus prevention, both in China and abroad.